Search results for "OUTCOME"

showing 10 items of 5148 documents

Early outcomes of patients with Marfan syndrome and acute aortic type A dissection.

2021

Acute aortic Stanford type A dissection remains a frequent and life-limiting event for patients with Marfan syndrome. Outcome results in this high-risk group are limited.The German Registry for Acute Aortic Dissection Type A collected the data of 56 centers between July 2006 and June 2015. Of 3385 patients undergoing operations for acute aortic Stanford type A dissection, 117 (3.5%) were diagnosed with Marfan syndrome. We performed a propensity score match comparing patients with Marfan syndrome with patients without Marfan syndrome in a 1:2 fashion.Patients with Marfan syndrome were significantly younger (42.9 vs 62.2 years; P  .001), predominantly male (76.9% vs 62.9%; P = .002), and less…

Pulmonary and Respiratory MedicineMarfan syndromeAortic archAortic dissectionmedicine.medical_specialtybusiness.industrySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Outcome analysismedicine.diseaseSurgeryMatched cohortmedicine.arteryPropensity score matchingmedicineSurgeryType a dissectionCardiology and Cardiovascular MedicinebusinessThe Journal of thoracic and cardiovascular surgery
researchProduct

Shedding some light on tricuspid intervention

2021

Background More than 1.6 million Americans have at least moderate to severe valvular tricuspid regurgitation, yet fewer than 8000 tricuspid valve operations are performed annually in the USA. The undertreatment for isolated tricuspid regurgitation might be related to the fact that in the past years no clear guidelines on 'how' and 'when' to treat tricuspid regurgitation were issued. Aims Sarris-Michopoulos and colleagues carried out a meta-analysis with the aim to investigate the role of tricuspid valve repair versus tricuspid valve replacement in patients with isolated tricuspid valve regurgitation. Material and methods Outcomes of patients with first-time surgery for isolated tricuspid va…

Pulmonary and Respiratory MedicineModerate to severecongenital hereditary and neonatal diseases and abnormalitiesmedicine.medical_specialtyPercutaneousContext (language use)Regurgitation (circulation)Intervention (counseling)Internal medicineHumansMedicinecardiovascular diseasesRetrospective StudiesHeart Valve Prosthesis ImplantationTricuspid valvebusiness.industryTricuspid Valve InsufficiencySurgeryTreatment Outcomemedicine.anatomical_structureVentricleCohortcardiovascular systemCardiologySurgeryTricuspid ValveTricuspid Valve RegurgitationCardiology and Cardiovascular Medicinebusiness
researchProduct

Phase II study of pemetrexed and cisplatin plus cetuximab followed by pemetrexed and cetuximab maintenance therapy in patients with advanced nonsquam…

2013

Abstract Objectives The aim was to determine if combined pemetrexed, cisplatin, and cetuximab was efficacious and safe as first-line treatment in advanced nonsquamous non-small cell lung cancer (NSCLC). Patients and methods In this single-arm, multicenter clinical trial, patients with Stage IIIB/IV nonsquamous NSCLC received first-line therapy consisting of pemetrexed (500mg/m 2 ) and cisplatin (75mg/m 2 ) on Day 1 (21-day cycles) plus weekly cetuximab (400mg/m 2 loading dose, then 250mg/m 2 ) for 4–6 cycles. Non-progressing patients received maintenance therapy consisting of pemetrexed and cetuximab as above until disease progression. All patients received vitamin supplementation, dexameth…

Pulmonary and Respiratory MedicineOncologyAdultMaleCancer Researchmedicine.medical_specialtyGuanineLung NeoplasmsPhases of clinical researchCetuximabPemetrexedAntibodies Monoclonal HumanizedLoading doseMaintenance ChemotherapyTranslational Research BiomedicalMaintenance therapyGlutamatesInternal medicineCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsmedicineClinical endpointHumansLung cancerSurvival rateAgedNeoplasm StagingCetuximabbusiness.industryInduction ChemotherapyMiddle Agedmedicine.diseasePemetrexedTreatment OutcomeOncologyFemaleCisplatinbusinessmedicine.drugLung cancer (Amsterdam, Netherlands)
researchProduct

Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: The cetuximab in advanced lung cancer (CALC1-E a…

2009

Background:Two parallel randomized phase 2 trialswere performed to choose the optimal way of combining cetuximab with gemcitabine in the first-line treatment of elderly (CALC1-E) and adult PS2 (CALC1-PS2) patients with advanced NSCLC. Methods: Stage IV or IIIB NSCLC patients, aged ≥70 years with PS 0–2 for CALC1-E or aged <70 with PS2 for CALC1-PS2, not selected for EGFR expression,were eligible. Patients were randomized to concomitant (gemcitabine, for a maximum of 6 cycles, plus cetuximab until progression) or sequential (gemcitabine, for a maximum of 6 cycles, followed by cetuximab) strategy. A selection design, with 1-year survival rate as the primary endpoint, was applied, requiring 58…

Pulmonary and Respiratory MedicineOncologyAdultMaleCancer Researchmedicine.medical_specialtyLung NeoplasmsAdolescentSettore MED/06 - Oncologia MedicaCetuximabNSCLCAntibodies Monoclonal HumanizedDeoxycytidinelaw.inventionYoung AdultRandomized controlled triallawInternal medicineCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansLung cancerPS2 patientSurvival analysisAgedCetuximabbusiness.industryCancerAntibodies MonoclonalMiddle Agedmedicine.diseaseGemcitabineGemcitabineSurgeryClinical trialTreatment OutcomeOncologyConcomitantPatient ComplianceFemalebusinessElderly patientmedicine.drug
researchProduct

Prognostic scoring system predictive of survival after surgical resection of esophageal carcinoma.

2013

BACKGROUND The aim of our study was to develop a prognostic index score for patients undergoing surgical resection for esophageal cancer that accurately determines survival with specific clinicopathological characteristics. METHODS Clinical, histological, and demographical variables of 475 patients were entered in an univariate and multivariate regression model, followed by individual calculation of the Prognostic Indicator Score and model validation via simulation. RESULTS Significant variables included in the scoring system were number of positive lymph nodes, pT, pL, R, obesity, and American Society of Anesthesiologist classification. Survival probability and its associated hazard functi…

Pulmonary and Respiratory MedicineOncologyAdultMalemedicine.medical_specialtyEsophageal NeoplasmsKaplan-Meier EstimateAdenocarcinomaRisk AssessmentDecision Support TechniquesPostoperative ComplicationsRisk FactorsStatistical significanceInternal medicineCarcinomaMedicineHumansComputer SimulationStage (cooking)AgedNeoplasm StagingProportional Hazards ModelsRetrospective StudiesAged 80 and overbusiness.industryPatient SelectionHazard ratioUnivariateCancerReproducibility of ResultsEsophageal cancerMiddle Agedmedicine.diseaseEsophagectomyTreatment OutcomeMultivariate AnalysisCarcinoma Squamous CellAdenocarcinomaSurgeryFemaleCardiology and Cardiovascular MedicinebusinessThe Thoracic and cardiovascular surgeon
researchProduct

Oral temozolomide in heavily pre-treated brain metastases from non-small cell lung cancer: phase II study

2005

Introduction: The primary tumour type most likely to metastasize to the brain is lung cancer. In heavily pre-treated patients, limited therapeutic option is available and the results of availability therapies reported in literature are disappointing. The present phase II study was designed to assess the efficacy and safety of temozolomide (TMZ) as palliative treatment for brain metastases (BrM) in NSCLC patients pre-treated with WBRT and at least one line of chemotherapy for metastatic brain disease. Material and methods: Temozolomide was administered orally at 150 mg/mq/day for five consecutive days for the first cycle, doses were increased to 200 mg/mq/day for 5 days every 28 days for sub…

Pulmonary and Respiratory MedicineOncologyMaleCancer Researchmedicine.medical_specialtyPalliative careLung NeoplasmsBrain metastasemedicine.medical_treatmentPhases of clinical researchAdministration OralPre-treatedInternal medicineCarcinoma Non-Small-Cell LungmedicineCarcinomaTemozolomideHumansAdverse effectLung cancerAntineoplastic Agents AlkylatingAgedChemotherapyTemozolomidebusiness.industryBrain NeoplasmsPalliative CareMiddle Agedmedicine.diseaseSurgeryDacarbazineTreatment OutcomeOncologyFemaleLung cancerbusinessProgressive diseasemedicine.drug
researchProduct

Cystic mucinous adenocarcinoma of the lung: a case report.

2011

Abstract Mucinous cystic tumors of the lung are uncommon, the preoperative pathologic diagnosis is difficult and their biological behavior is still controversial. We report the case of a patient with a clinically benign cystic lesion that post-operatively showed to be consistent with an invasive adenocarcinoma arising in a mucinous cystadenoma of the lung, We underline the difficulty of the clinical pre-operative diagnosis of this cystic neoplasia radiologically mimicking a hydatid cyst, and we report the negative TTF1 immunostaining potentially misleading in the differential diagnosis with metastatic mucinous carcinomas. Finallly, we evidence the presence of a pre-existing mucinous benign …

Pulmonary and Respiratory MedicinePathologymedicine.medical_specialtyLung NeoplasmsProliferation indexCystic mucinous adenocarcinoma lungSettore MED/21 - Chirurgia Toracicalcsh:SurgeryEnzyme-Linked Immunosorbent AssayCase ReportSettore MED/08 - Anatomia PatologicaMalignant transformationMetastasislcsh:RD78.3-87.3Diagnosis DifferentialFatal OutcomeCystadenoma MucinousBronchoscopymedicineAdenocarcinoma of the lungHumansMucinous cystadenomabusiness.industrylcsh:RD1-811General MedicineMiddle Agedmedicine.diseaseImmunohistochemistrylcsh:AnesthesiologyCystadenomaAdenocarcinomaSurgeryFemaleRadiologyDifferential diagnosisCardiology and Cardiovascular MedicinebusinessTomography X-Ray ComputedJournal of cardiothoracic surgery
researchProduct

Spontaneous pneumomediastinum and subcutaneous emphysema as a complication of asthma in children: case report and literature review

2016

Background:Spontaneous pneumomediastinum (SPM) is an uncommon disorder. It is rarely reported in paediatric patients and may be accompanied by subcutaneous emphysema. It is usually benign and self-limiting, with only supportive therapy being needed, but severe cases may require invasive measures. Asthma exacerbations have classically been described as a cause of SPM. However, detailed descriptions in asthmatic children are scarce. We aimed at improving the current understanding of the features of SPM and subcutaneous emphysema, and outcomes, by means of a case report and a systematic review.Methods:For the systematic review a literature search was performed in PubMed to identify reported ca…

Pulmonary and Respiratory MedicinePediatricsmedicine.medical_specialtyspontaneous pneumomediastinumUncommon disorder03 medical and health sciences0302 clinical medicinechildrensystematic review030225 pediatricsMedicinecase reportHumansPharmacology (medical)Sublingual immunotherapy030212 general & internal medicineAnti-Asthmatic AgentsChildMediastinal EmphysemaAsthmaOriginal Researchlcsh:RC705-779business.industryAsthma symptomssubcutaneous emphysemalcsh:Diseases of the respiratory systemasthmamedicine.diseaseDyspneaTreatment OutcomeCoughSupportive psychotherapyAnesthesiaSpontaneous pneumomediastinumFemalemedicine.symptombusinessComplicationSubcutaneous emphysemaTherapeutic Advances in Respiratory Disease
researchProduct

The Neochord Procedure After Failed Surgical Mitral Valve Repair.

2021

Surgical mitral valve reintervention is associated with significant morbidity and mortality, and repeat repair is not always feasible. We examine the clinical outcomes of the NeoChord procedure after failed conventional mitral valve repair. A total of 312 patients were treated with the NeoChord repair procedure between January 2014 and December 2018 at 5 European centers. Clinical and echocardiographic data were reviewed to identify patients who had a prior surgical mitral valve repair procedure. The primary endpoint (Patient Success) was a composite of placement of at least 2 neochordae and end-procedure mitral valve regurgitation (MR) ≤ mild, freedom from death, stroke, structural or func…

Pulmonary and Respiratory MedicineReoperationmedicine.medical_specialtymedicine.medical_treatmentMR recurrence030204 cardiovascular system & hematologylaw.invention03 medical and health sciences0302 clinical medicinelawMitral valvemedicineHumansBeating-heart surgery; MR recurrence; MV repair failure; Neochords; Off-pump mitral valve surgeryAortic dissectionHeart Valve Prosthesis ImplantationMV repair failureMitral valve repairMitral regurgitationEjection fractionBeating-heart surgerybusiness.industryOff-pump mitral valve surgeryMitral Valve InsufficiencyAtrial fibrillationGeneral Medicinemedicine.diseaseIntensive care unitSurgerymedicine.anatomical_structureTreatment OutcomeNeochords030228 respiratory systemEchocardiographyMitral ValveSurgeryCardiology and Cardiovascular MedicineMitral valve regurgitationbusinessSeminars in thoracic and cardiovascular surgery
researchProduct

Improved identification of thrombolysis candidates amongst intermediate-risk pulmonary embolism patients: implications for future trials.

2017

Defining a “higher-risk” population among intermediate-risk patients with pulmonary embolism included in PEITHO http://ow.ly/JM7u30hcSgN

Pulmonary and Respiratory MedicineResearch designAdultRiskmedicine.medical_specialtymedicine.medical_treatmentPopulationMEDLINEHemorrhageComorbidity030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineText miningFibrinolytic AgentsmedicineHumansThrombolytic Therapy030212 general & internal medicineProspective StudiesIntensive care medicineeducationProspective cohort studyeducation.field_of_studybusiness.industryPatient SelectionAnticoagulantsThrombolysismedicine.diseasePrognosisComorbidityPulmonary embolismTreatment OutcomeEchocardiographyResearch DesignTenecteplasebusinessPulmonary EmbolismThe European respiratory journal
researchProduct